The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Drapkina O.M.

National Medical Research Center for Therapy and Preventive Medicine;
A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Berns S.A.

National Medical Research Center for Therapy and Preventive Medicine

Gorshkov A.Yu.

National Medical Research Center for Therapy and Preventive Medicine

Ryzhakova L.N.

National Medical Research Center for Therapy and Preventive Medicine

Zhdanova O.V.

National Medical Research Center for Therapy and Preventive Medicine

Chashchin M.G.

National Medical Research Center for Therapy and Preventive Medicine

Litinskaya O.A.

National Medical Research Center for Therapy and Preventive Medicine

Savicheva A.A.

National Medical Research Center for Therapy and Preventive Medicine

Strelkova A.V.

National Medical Research Center for Therapy and Preventive Medicine

Comparative assessment of efficacy and immunogenicity of Gam-COVID-Vac and CoviVac vaccines against SARS-CoV-2

Authors:

Drapkina O.M., Berns S.A., Gorshkov A.Yu., Ryzhakova L.N., Zhdanova O.V., Chashchin M.G., Litinskaya O.A., Savicheva A.A., Strelkova A.V.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2022;25(12): 82‑87

DOI: 10.17116/profmed20222512182

Read: 1494 times

Download PDF (RU)
Contact the author
Table of contents

COMPARATIVE ASSESSMENT OF EFFICACY AND IMMUNOGENICITY OF GAM-COVID-VAC AND COVIVAC VACCINES AGAINST SARS-COV-2
COMPARATIVE ASSESSMENT OF EFFICACY AND IMMUNOGENICITY OF GAM-COVID-VAC AND COVIVAC VACCINES AGAINST SARS-COV-2

To cite this article:

Drapkina OM, Berns SA, Gorshkov AYu, et al. . Comparative assessment of efficacy and immunogenicity of Gam-COVID-Vac and CoviVac vaccines against SARS-CoV-2. Russian Journal of Preventive Medicine. 2022;25(12):82‑87. (In Russ.)
https://doi.org/10.17116/profmed20222512182

 
 
 
Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Morphofunctional and biochemical dete­rminants of endo­thelial function in patients with a new coro­navirus infe­ction COVID-19. Russian Journal of Preventive Medi­cine. 2024;(10):90-96
Heart failure with preserved ejection fraction: morphofunctional state of the heart throughout 2 years after COVID-19 pneumonia. Russian Cardiology Bulletin. 2024;(3):53-61
ALDH1, CD133, CD34-positive cancer stem cells in lung adenocarcinoma in patients who had a new coro­navirus infe­ction and retained the persistence of viral proteins in the lung tissue. Russian Journal of Archive of Pathology. 2024;(5):5-14
Factors affe­cting the quality of life of patients with neurological mani­festations of post-COVID syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):44-50
«Cytokine storm» as an immu­nopathologic reaction in pregnant women in the first trimester. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):19-24
Inci­dence of sudden cardiac death among diseases of the circulatory system during the COVID-19 pandemic in the Penza region. Fore­nsic Medi­cal Expe­rtise. 2024;(5):10-14
Labo­ratory tests for diagnostics of cell immu­nity against SARS-CoV-2 (review of lite­rature). Labo­ratory Service. 2024;(3):31-36
Loca­lization features of FAP-positive acti­vated stro­mal cells in fibrosis in patients with new coro­navirus infe­ction COVID-19. Russian Journal of Archive of Pathology. 2024;(6):5-14
The role of drug Cyto­flavin in the correction of dysautonomia in patients with post-COVID syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):140-146
Lapa­roscopic appe­ndectomy for appe­ndiceal muco­cele in a patient with COVID-19. Endo­scopic Surgery. 2024;(6):41-45
Abstract:

The medical community is interested in the duration of immune protection and the level of specific antibodies (AB) that can prevent reinfection with SARS-CoV-2.

OBJECTIVE

To perform a comparative evaluation of efficacy and immunogenicity of Gam-COVID-Vac and CoviVac vaccines against SARS-CoV-2 in a prospective observational study.

MATERIAL AND METHODS

The following vaccines were used for the vaccination of subjects (n=3322) aged 18 years and older: Gam-COVID-Vac — 1.622 (48.8%) subjects (group I), CoviVac — 1.700 (51.2%) subjects (group II). Vaccinated subjects were followed up for 6 study visits: before the 1st component of the vaccine, before the 2nd component of the vaccine, 42 days, 3 months, 6 months, and 12 months after the 1st component of the vaccine. Immunoglobulin G (IgG) levels of AB to S protein were compared after the injection of Gam-COVID-Vac and CoviVac vaccines using an enzyme immunoassay. Statistical processing of the obtained data was performed using IBM SPSS Statistics v. 24 and MedCalc v. 20.104 software.

RESULTS

Group I subjects showed an increase in specific AB (IgG) levels to SARS-CoV-2 S protein from visit 1 to visits 2 and 3 (p<0.05). In more extended follow-up periods (visits 5, 6), AB levels in groups I and II did not differ significantly and remained sufficiently high by visit 6. Within one year of follow-up, the incidence of COVID-19 (confirmed by polymerase chain reaction) was significantly (p<0.01) lower in the Gam-COVID-Vac group (group I): 22.2% vs. 45.2% in the CoviVac group (group II). The maximum number of days (p<0.05) before the COVID-19 infection was observed in those vaccinated with Gam-COVID-Vac (221 days) compared to those immunized with CoviVac (159 days).

CONCLUSION

The Gam-COVID-Vac vaccine is more effective against COVID-19 and induces a more rapid response of the humoral immune system than the CoviVac vaccine. However, the duration of the humoral immune response after administration of Gam-COVID-Vac and CoviVac was similar.

Keywords:

SARS-CoV-2
vaccination
immunogenicity
humoral immunity
COVID-19
Gam-COVID-Vac
CoviVac

Authors:

Drapkina O.M.

National Medical Research Center for Therapy and Preventive Medicine;
A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Berns S.A.

National Medical Research Center for Therapy and Preventive Medicine

Gorshkov A.Yu.

National Medical Research Center for Therapy and Preventive Medicine

Ryzhakova L.N.

National Medical Research Center for Therapy and Preventive Medicine

Zhdanova O.V.

National Medical Research Center for Therapy and Preventive Medicine

Chashchin M.G.

National Medical Research Center for Therapy and Preventive Medicine

Litinskaya O.A.

National Medical Research Center for Therapy and Preventive Medicine

Savicheva A.A.

National Medical Research Center for Therapy and Preventive Medicine

Strelkova A.V.

National Medical Research Center for Therapy and Preventive Medicine

Received:

23.11.2022

Accepted:

08.12.2022

Close metadata

References:

  1. Juno JA, Tan HX, Lee WS, Reynaldi A, Kelly HG, Wragg K, Esterbauer R, Kent HE, Batten CJ, Mordant FL, Gherardin NA, Pymm P, Dietrich MH, Scott NE, Tham WH, Godfrey DI, Subbarao K, Davenport MP, Kent SJ, Wheatley AK. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nature Medicine. 2020;26(9):1428-1434. https://doi.org/10.1038/s41591-020-0995-0
  2. Koutsakos M, Rowntree LC, Hensen L, Chua BY, van de Sandt CE, Habel JR, Zhang W, Jia X, Kedzierski L, Ashhurst TM, Putri GH, Marsh-Wakefield F, Read MN, Edwards DN, Clemens EB, Wong CY, Mordant FL, Juno JA, Amanat F, Audsley J, Holmes NE, Gordon CL, Smibert OC, Trubiano JA, Hughes CM, Catton M, Denholm JT, Tong SYC, Doolan DL, Kotsimbos TC, Jackson DC, Krammer F, Godfrey DI, Chung AW, King NJC, Lewin SR, Wheatley AK, Kent SJ, Subbarao K, McMahon J, Thevarajan I, Nguyen THO, Cheng AC, Kedzierska K. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Reports. Medicine. 2021;2(3):100208. https://doi.org/10.1016/j.xcrm.2021.100208
  3. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, Jia X, Nicholson S, Catton M, Cowie B, Tong SYC, Lewin SR, Kedzierska K. Breadth of concomitant immune responses prior to patient recovery: A case report of non-severe COVID-19. Nature Medicine. 2020;26(4):453-455.  https://doi.org/10.1038/s41591-020-0819-2
  4. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine. 2021;27(7):1205-1211. https://doi.org/10.1038/s41591-021-01377-8
  5. Kedzierska K, Thomas PG. Count on us: T cells in SARS-CoV-2 infection and vaccination. Cell Reports. Medicine. 2022;3(3):100562. https://doi.org/10.1016/j.xcrm.2022.100562
  6. Rossi AH, Ojeda DS, Varese A, Sanchez L, Gonzalez Lopez Ledesma MM, Mazzitelli I, Alvarez Juliá A, Oviedo Rouco S, Pallarés HM, Costa Navarro GS, Rasetto NB, Garcia CI, Wenker SD, Ramis LY, Bialer MG, de Leone MJ, Hernando CE, Sosa S, Bianchimano L, Rios AS, Treffinger Cienfuegos MS, Caramelo JJ, Longueira Y, Laufer N, Alvarez DE, Carradori J, Pedrozza D, Rima A, Echegoyen C, Ercole R, Gelpi P, Marchetti S, Zubieta M, Docena G, Kreplak N, Yanovsky M, Geffner J, Pifano M, Gamarnik AV. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. Cell Reports Medicine. 2021;2(8): 100359. https://doi.org/10.1016/j.xcrm.2021.100359
  7. Pis’mo Ministerstva zdravookhraneniya Rossijskoj Federatsii ot 29 iyunya 2021 g. №30-4/I/2-9825 «Vremennye metodicheskie rekomendatsii. Poryadok provedeniya vaktsinacii vzroslogo naseleniya protiv COVID-19». (In Russ.). Accessed November 23, 2022. https://rosreestr.gov.ru/upload/Doc/09-upr/%D0%9C%D0%B5%D1%82%D0%BE%D0%B4_%D1%80%D0%B5%D0%BA%D0%BE%D0%BC_%D0%9C%D0%B8%D0%BD%D0%B7%D0%B4%D1%80%D0%B0%D0%B2%D0%B0%20%D0%BE%D1%82%2029.06.2021.pdf
  8. Gosudarstvennyj reestr lekarstvennykh sredstv. LP-007967. Konvasel®. (In Russ.). Accessed November 23, 2022. https://grls.rosminzdrav.ru/Default.aspx
  9. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet. 2020;396(10255):887-897.  https://doi.org/10.1016/S0140-6736(20)31866-3
  10. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397(10275):671-688.  https://doi.org/10.1016/S0140-6736(21)00234-8
  11. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC, Hirsch I, Humphries HE, Jepson B, Kelly EJ, Plested E, Shoemaker K, Thomas KM, Vekemans J, Villafana TL, Lambe T, Pollard AJ, Voysey M; Oxford COVID Vaccine Trial Group. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine. 2021;27(11):2032-2040. https://doi.org/10.1038/s41591-021-01540-1
  12. Hung IFN, Poland GA. Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster. The Lancet. 2021;397(10277):854-855.  https://doi.org/10.1016/S0140-6736(21)00528-6
  13. Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, Bermúdez-González MC, Bielak DA, Carreño JM, Chernet RL, Eaker LQ, Ferreri ED, Floda DL, Gleason CR, Hamburger JZ, Jiang K, Kleiner G, Jurczyszak D, Matthews JC, Mendez WA, Nabeel I, Mulder LCF, Raskin AJ, Russo KT, Salimbangon AT, Saksena M, Shin AS, Singh G, Sominsky LA, Stadlbauer D, Wajnberg A, Simon V. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. The New England Journal of Medicine. 2021;384(14):1372-1374. https://doi.org/10.1056/NEJMc2101667
  14. Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, Frias EC, Stewart JL, Van Eyk JE, Braun JG, Cheng S, Sobhani K. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nature Medicine. 2021;27(6):981-984.  https://doi.org/10.1038/s41591-021-01325-6
  15. Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, Derqui-Fernandez N, Barnett JL, Whitfield MG, Varro R, Charlett A, Kundu R, Fenn J, Cutajar J, Quinn V, Conibear E, Barclay W, Freemont PS, Taylor GP, Ahmad S, Zambon M, Ferguson NM, Lalvani A; ATACCC Study Investigators. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: A prospective, longitudinal, cohort study. The Lancet. Infectious Diseases. 2022;2(2):183-195.  https://doi.org/10.1016/S1473-3099(21)00648-4
  16. Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, Khunti K, Alwan NA, Walker AS. Trajectory of long covid symptoms after COVID-19 vaccination: community based cohort study. BMJ. 2022;377:e069676. https://doi.org/10.1136/bmj-2021-069676
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.